Key Takeaways Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in ...

AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its ...

A trial drug has kept Desiree Dufour's breast cancer at bay — and now, the medication has been approved by the FDA. She has ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a ...

Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...

While growing evidence suggests that there’s a link between blood iron levels and the development of Alzheimer’s disease, new ...

The centerpiece drug of AbbVie’s $9 billion acquisition of Cerevel Therapeutics has failed in two Phase II clinical trials ...

AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US ...

The US Food and Drug Administration (FDA) sometimes allows cancer drugs with accelerated approvals to remain on the market ...

A new Dublin-headquartered company for rare diseases, Oranda Therapeutics, is seeking to raise €35 million in an early-stage ...